AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 09:05 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM, will present...
Potential COVID Spike Protein Detoxification Regime Discussed in Journal of American Physicians and Surgeons (AAPS)
August 31, 2023 14:29 ET
|
Association of American Physicians and Surgeons
TUCSON, Ariz., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Disabling post-COVID symptoms (“long COVID”) and vaccine injury syndromes are increasingly prevalent, and there is no currently accepted treatment...
Ways to Counteract COVID Spike Protein Discussed in Journal of American Physicians and Surgeons (AAPS)
August 30, 2023 11:28 ET
|
Association of American Physicians and Surgeons
TUCSON, Ariz., Aug. 30, 2023 (GLOBE NEWSWIRE) -- The SARS-CoV-2 spike protein found in cells and tissues after COVID-19 respiratory illness and COVID-19 vaccination, which is thought to account for...
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update
August 15, 2023 06:45 ET
|
AIM ImmunoTech Inc.
– Continued operational execution across pipeline towards multiple clinical and regulatory value-driving milestones expected in the second half of 2023 – Company to host conference call and...
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
August 09, 2023 09:05 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss...
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
August 08, 2023 08:05 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the completion of enrollment in the company’s Phase 2 study evaluating Ampligen® as a...
SSA’s New Guide: A Positive Step For Long COVID Sufferers, Allsup Ready To Assist With SSDI Claims
July 31, 2023 16:49 ET
|
Allsup
Belleville, Illinois, July 31, 2023 (GLOBE NEWSWIRE) -- The Social Security Administration (SSA) has issued new guidance for long COVID sufferers. The guide offers a clearer picture as to how this...
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
July 10, 2023 08:05 ET
|
AIM ImmunoTech Inc.
Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 ...
AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series
July 05, 2023 08:35 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
Aviv Clinics Spotlights New Hyperbaric Oxygen Therapy Study Sharing Its Effect on Myocardial Function in Post-COVID-19 Patients
June 13, 2023 09:10 ET
|
Aviv Clinics
ORLANDO, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- Aviv Clinics, one of the most advanced medical clinics in the world, is sharing the results of a new study that shows that a unique hyperbaric oxygen...